Posaconazole: Difference between revisions

From IDWiki
(added EUCAST ECOFFs and breakpoints)
No edit summary
Line 1: Line 1:
  +
== Background ==
==Therapeutic Drug Monitoring==
 
   
  +
* Azole antifungal
*Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
 
  +
*For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
 
  +
=== Pharmacokinetics and Pharmacodynamics ===
*For treatment, target trough >1 mg/L
 
  +
  +
* Generally distributes well, with the notable exception of non-inflamed brain
   
 
===Clinical Breakpoints===
 
===Clinical Breakpoints===
Line 95: Line 97:
 
|>0.25
 
|>0.25
 
|}
 
|}
  +
  +
== Dosing ==
  +
 
=== Therapeutic Drug Monitoring ===
 
*Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
 
*For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
 
*For treatment, target trough >1 mg/L
   
 
== Safety ==
 
== Safety ==

Revision as of 09:39, 22 October 2024

Background

  • Azole antifungal

Pharmacokinetics and Pharmacodynamics

  • Generally distributes well, with the notable exception of non-inflamed brain

Clinical Breakpoints

Species ECV (μg/mL) Breakpoints (μg/mL)
S I SDD R
Candida albicans 0.06 ≤0.06 ≥0.12
Candida dubliniensis
Candida glabrata 2
Candida guilliermondii 0.5
Candida kefyr 0.25
Candida krusei 0.5
Candida lusitaniae 0.12
Candida parapsilosis 0.25 ≤0.06 ≥0.12
Candida tropicalis 0.12 ≤0.06 ≥0.12
Cryptococcus neoformans
Cryptococcus gattii
Aspergillus flavus 0.5
Aspergillus fumigatus 0.25 ≤0.125 >0.25
Aspergillus nidulans 0.5
Aspergillus niger 0.5
Aspergillus terreus 0.25 ≤0.125 >0.25

Dosing

Therapeutic Drug Monitoring

  • Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
  • For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
  • For treatment, target trough >1 mg/L

Safety

Adverse Events

  • Liver toxicity
    • Generally transient and asymptomatic and self-limited
    • See also LiverTox